Frankfurt Rights

Your Search Results(showing 82)

    Filter your results
    Filter your results
    • Events
    • Category
    • Seller
    • Publication Year
    • Original Language
    • Rights Available in Language
    • Publish Status
    • Publication Country or region
    • Rights Available in Territory
    • Offer Type
    • Permission selling companies
    • More
    View items
    • Trusted Partner
      Interactions between Medicines and Food
      2020

      Interactions between Medicines and Food

      by Prof. Dr. Martin Smollich and Dr. Julia Podlogar

      Interactions between medicines and foodstuffs may be just as clinically relevant as interactions between individual drugs. A single meal contains several hundred potentially interacting compounds that, in an individual patient, may be the deciding factor as to whether a treatment is successful or not. The resulting, sometimes serious risks are not known to most patients – nor to many physicians and pharmacists. This practical handbook enables anyone interested in applied pharmacotherapy to keep abreast of the complex field of drug interactions. The authors – proven experts in clinical pharmacology and pharmaconutrition – describe the most important interactions and give concrete recommendations for action. Tables and overviews permit fast access to potentially problematic combinations. This completely updated edition now also includes information about fruit juices and curcumin as well as a new chapter on food interactions in oncology.

      More
    • Trusted Partner
      Assemblages of cancer
      Science & Mathematics
      February 2025

      Assemblages of cancer

      Experiences and contexts of breast cancer in the UK, France and Italy

      by Cinzia Greco

      Assemblages of cancer illustrates the tensions in the experiences and context of breast cancer in Western Europe. Breast cancer is presented as a success story in oncology, especially in countries with advanced, universal healthcare systems. At the same time, individual experiences are shaped by uncertainty, local variability of healthcare provisions, and the need for patients to assemble information about the treatments, knowledge on healthcare systems navigation, and different processes of meaning-making to manage the uncertainty and variability characterising individual outcomes. The book explores both how individual bodies and experiences are transformed by different local medical practices, institutions and discourses of breast cancer and how patients need to find their own way in these contexts. Assemblages of cancer is based on ten years of ethnographic work with patients and medical professionals in the UK, France and Italy.

      More
    • Trusted Partner
      Complementary Oncology
      October 2005

      Complementary Oncology

      by Beuth, Josef, Moss, Ralph

      More
    • Trusted Partner
      Oral Health and Oral Care
      Health & Personal Development

      Oral Health and Oral Care

      Practice Manual for Nurses, Nursing, Dental and Dental Prophylaxis Assistants

      by Thomas Gottschalck

      A healthy, cared­for mouth prevents the occurrence of oral diseases and systemic contingent diseases. Every day, professional hygienists are con­fronted with the oral care of their pa­tients and need to be informed of new developments in dentistry, pharmacol­ogy, technology, and care methods. This book offers sound action recom­mendations for hygienists and dental assistants with vivid illustrations. There are clear descriptions of the anatomical and physiological basics of oral mucosa, teeth, and the oral cavity ecosystem. Practical illustrations of the connections between oral health and general health, debilitating risks, handling modern den­tures, assessment of oral changes, oral approaches through basal stimulation and dietary recommendations are pro­vided. Consideration is also given to oral hygiene in special settings, for example, in the case of neurological, psychologi­cal, or mental impairments as well as people receiving geriatric, oncological, intensive, or palliative care.

      More
    • Trusted Partner
      Complications in Non-vascular Interventional Therapy and Interventional Oncology: Case-based Solutions
      June 2019

      Complications in Non-vascular Interventional Therapy and Interventional Oncology: Case-based Solutions

      by Müller-Hülsbeck, Stefan; Jahnke, Thomas

      More
    • Trusted Partner
      Science, Being, & Becoming
      Mind, Body, Spirit

      Science, Being, & Becoming

      The Spiritual Lives of Scientists

      by Paul J. Mills, Ph.D.

      Spirituality is the Final Frontier for ScienceContrary to popular belief, not all scientists are materialists fervently discounting the spiritual. Science, Being, & Becoming is about the spiritual lives of scientists, their actual transpersonal, metaphysical and mystical experiences. The book's material is derived from intimate interviews with over 30 scientists as they describe the circumstances under which they had the experiences and how those experiences changed their consciousness, transformed their belief systems about the nature of the world, and changed their scientific work.

      More
    • Trusted Partner
      Therapeutic Strategies in Veterinary Oncology
      Medicine
      April 2023

      Therapeutic Strategies in Veterinary Oncology

      by Chand Khanna, Nicole Amato, Jacob Cawley, Steven Dow, Joelle Fenger, Andi Flory, Ira Gordon, Kayla Harding, Kelvin Kow, Cheryl London, Nicola Mason, Arata Matsuyama, Jonathan Mochel, Anthony Mutsaers, Henrik Rönnberg, Wesley Wierson

      This book is a comprehensive resource for veterinary oncologists and trainees, covering therapeutic strategies used in the treatment of veterinary patients. In the setting of a rapidly changing field like oncology, this timely text focuses on mechanisms of action and biological rationale rather than current specific clinical recommendations, allowing current and future clinicians to adapt treatment approaches as our understanding of the biology of cancer evolves. With each chapter written by experts in their field, this book provides informative figures that convey this biological understanding and rationale of therapy. It starts from the mechanisms of treatment as we currently understand them, covering radiation therapy, chemotherapy options, enzyme therapy, gene editing, inhibitors, and many more. Dispensing vital, detailed and practical information about the different therapeutic strategies available, this book is a vital resource for practicing veterinarians, while also providing students of veterinary oncology with a better understanding of the key differences between different treatment strategies.

      More
    • Complex General Surgical Oncology: a Case-Based Approach (Volume 1)
      Surgical oncology
      November 2013

      Complex General Surgical Oncology: a Case-Based Approach (Volume 1)

      by Jason B Fleming, Daniel E Abbott

      Surgical oncology is a rapidly evolving field. Through increasingly sophisticated technologies and interventional techniques, and continued basic science breakthroughs, care of the cancer patient is ever improving. A cornerstone of this improvement is a continual evaluation and recognition of evidence-based changing practice patterns. This reality forms the basis for this two-volume text, focusing on diagnostic and treatment algorithms to maximize quality care for the surgical oncology patient. To engage the reader with real-world, patient-centered learning, this book consists of case-based scenarios and follow-up questions addressing key concepts of complex surgical oncology. This first volume of 18 chapters focuses on a variety of breast pathology, followed by examination of endocrine, soft tissue and esophageal malignancies, providing an excellent resource to guide optimal care for patients.

      More
    • Complex General Surgical Oncology: a Case-Based Approach (Volume 2)
      Surgical oncology
      November 2013

      Complex General Surgical Oncology: a Case-Based Approach (Volume 2)

      by Jason B Fleming, Daniel E Abbott

      Surgical oncology is a rapidly evolving field. Through increasingly sophisticated technologies and interventional techniques, and continued basic science breakthroughs, care of the cancer patient is ever improving. A cornerstone of this improvement is a continual evaluation and recognition of evidence-based changing practice patterns. This reality forms the basis for this two-volume text, focusing on diagnostic and treatment algorithms to maximize quality care for the surgical oncology patient. To engage the reader with real-world, patient-centered learning, this book consists of case-based scenarios and follow-up questions addressing key concepts of complex surgical oncology. This first volume of 18 chapters focuses on a variety of breast pathology, followed by examination of endocrine, soft tissue and esophageal malignancies, providing an excellent resource to guide optimal care for patients.

      More
    • Oncology Times
      Medicine
      2001

      Oncology Times

      The Independent Hem/Onc News Source

      by Edited by Serena Stockwell

      24 issues/yr - 2013 Volume(s) - 33 www.oncology-times.com This award-winning, independent newspaper, mailed to over 39,000 cancer specialists, reports on breaking clinical news in oncology, radiology, surgery, chemotherapy, and biological and gene therapy, as well as the professional, political, reimbursement, and practice management issues that affect those treating cancer patients. Included in this publication--the leading newspaper in oncology--are hard-hitting editorials and special reports.

      More
    • Nanotechnology and Oncology
      Oncology
      July 2011

      Nanotechnology and Oncology

      Workshop Summary

      by Margie Patlak and Christine Micheel, Rapporteurs; National Cancer Policy Forum; Board on Health Care Services; Institute of Medicine

      One way scientists are working to overcome challenges in cancer treatment and improve cancer care is through nanotechnology. Nanotechnology, engineered materials that make use of the unique physical properties, presents a new array of medical prospects that will revolutionize cancer prevention, diagnosis, and treatment practices. Giving new hope to patients, practitioners, and researchers alike, nanotechnology has the potential to translate recent discoveries in cancer biology into clinical advances in oncology. While public investments in nanotechnology for cancer continue to increase, medical products based on nanotechnology are already on the market. The National Cancer Policy forum held a workshop July 12-13, 2010, to explore challenges in the use of nanotechnology in oncology. Nanotechnology and Oncology evaluates the ongoing discussion on the role of nanotechnology in cancer as it relates to risk management, treatment, and regulatory policy. Assessments on nanomedicine and the physical properties of nanomaterials were presented during the workshop, along with an appraisal of the current status of research and development efforts.

      More
    • Oncology Times UK Version
      Medicine
      2004

      Oncology Times UK Version

      The Independent Hem/Onc News Source

      by Edited by Serena Stockwell

      Monthly - 2013 Volume(s) - 8 www.oncology-times-uk.com This award-winning, independent newspaper, mailed to over 39,000 cancer specialists, reports on breaking clinical news in oncology, radiology, surgery, chemotherapy, and biological and gene therapy, as well as the professional, political, reimbursement, and practice management issues that affect those treating cancer patients. Included in this publication--the leading newspaper in oncology--are hard-hitting editorials and special reports

      More
    • The Long Tale of Tears and Smiles
      Biography & True Stories
      June 2021

      The Long Tale of Tears and Smiles

      An Oncologist's Journey

      by Rana Bitar, M.D.

      The Long Tale Of Tears And Smiles explores an immigrant oncologist’s journey of triumphs and struggles, from growing up in Syria, to the tragic death of her brother, to her experiences as a young immigrant medical student and trainee in the USA. Walk through her anguish witnessing the civil war in Syria and its devastation; see her become a practitioner, watching the field of oncology evolves throughout the years.This narrative-driven case study interweaves the stories of the patients Bitar has cared for with her own life stories; it reflects on how her patients’ lives and the stories of their survival or death inspired and changed her life starting and raising a family. Each patient’s approach to illness and end-of-life is as unique as they are, and each person’s journey contains unexpected lessons.In the space between life and death, Bitar’s profession thrives; and in that space, she can search for the meaning of her existence.

      More
    • Implementing a National Cancer Clinical Trials System for the 21st Century
      Health systems & services
      September 2011

      Implementing a National Cancer Clinical Trials System for the 21st Century

      Workshop Summary

      by Alison Mack and Sharyl J. Nass, Rapporteurs; National Cancer Policy Forum; Institute of Medicine; An American Society of Clinical Oncology and Institute of Medicine Workshop

      Clinical trials enable scientific discoveries to advance patient care, in addition to informing and guiding subsequent research. The National Cancer Institute's (NCI's) Clinical Trials Cooperative Group Program works to advance patient care and research. The Cooperative Group Program has been instrumental in establishing the standards for cancer patient care and clinical research methods. Despite broad participation in the program, financial strain and procedural burdens limit the ability of the Cooperative Group Program to undertake medical practice-changing clinical research. Thus, the Institute of Medicine's (IOM's) National Cancer Policy Forum and the American Society of Clinical Oncology held a workshop on March 21, 2011 to follow up on the 2010 IOM report, A National Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, which made recommendations to strengthen the NCI Cooperative Group Program. In keeping with the established commitment to excellence Implementing a National Cancer Clinical Trials System for the 21st Century outlines how to improve the current system by incorporating innovative science and trial design into cancer clinical trials. It also examines the impact of increasing quality in regards to speed, efficiency, design, launch, and conduct, as well as improving prioritization, and incentivized participation.

      More
    • Implementing a National Cancer Clinical Trials System for the 21st Century
      Oncology
      September 2013

      Implementing a National Cancer Clinical Trials System for the 21st Century

      Second Workshop Summary

      by An American Society of Clinical Oncology and Institute of Medicine Workshop; Sharyl J. Nass and Margie Patlak, Rapporteurs; National Cancer Policy Forum; Board on Health Care Services; Institute of Medicine

      The National Clinical Trials Network (NCTN) supported by the National Cancer Institute (NCI) has played an integral role in cancer research and in establishing the standard of care for cancer patients for more than 50 years. Formerly known as the NCI Clinical Trials Cooperative Group Program, the NCTN is comprised of more than 2,100 institutions and 14,000 investigators, who enroll more than 20,000 cancer patients in clinical trials each year across the United States and internationally. Recognizing the recent transformative advances in cancer research that necessitate modernization in how cancer clinical trials are run, as well as inefficiencies and other challenges impeding the national cancer clinical trials program, the NCI asked the IOM to develop a set of recommendations to improve the federally funded cancer clinical trials system. These recommendations were published in the 2010 report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. In early 2011, the NCPF and the American Society of Clinical Oncology (ASCO) held a workshop in which stakeholders discussed the changes they planned to implement in response to the IOM goals and recommendations. Two years later, on February 11-12, 2013, in Washington, DC, the NCPF and ASCO reconvened stakeholders to report on the changes they have made thus far to address the IOM recommendations. At this workshop, representatives from the NCI, the NCTN, comprehensive cancer centers, patient advocacy groups, the Food and Drug Administration (FDA), industry, and other stakeholders highlighted the progress that has been made in achieving the goals for a reinvigorated national cancer clinical trials system. Implementing a National Cancer Clinical Trials System for the 21st Century is a summary of that workshop.

      More
    • Examining Access to Nutrition Care in Outpatient Cancer Centers
      Dietetics & nutrition
      February 2017

      Examining Access to Nutrition Care in Outpatient Cancer Centers

      Proceedings of a Workshop

      by Leslie Pray and Ann L. Yaktine, Rapporteurs; Food and Nutrition Board; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine

      An estimated 90 percent of oncology patients in the United States receive treatment in outpatient cancer centers and clinics. This change from the older model of inpatient care has important implications for overall quality of care for oncology patients and nutritional care in particular. Amidst growing concern about access to oncology nutrition services, combined with growing recognition of the importance of providing nutritional care to optimize oncology treatment outcomes and maximize quality of life among both patients and survivors of cancer, the National Academies of Sciences, Engineering, and Medicine convened a public workshop in March 2016 to explore evolving interactions between nutritional care, cancer, and health outcomes. Participants explored how health outcomes and survival of cancer patients in outpatient cancer centers are affected by current standards for nutritional services, nutritional interventions, and benefits associated with oncology patient access to medical nutrition therapy. They also studied the cost of outpatient nutritional care and assessed costâ€"benefit relationships between oncology nutrition services and health outcomes and survival. This publication summarizes the presentations and discussions from the workshop.

      More
    • Extending the Spectrum of Precompetitive Collaboration in Oncology Research
      Oncology
      September 2010

      Extending the Spectrum of Precompetitive Collaboration in Oncology Research

      Workshop Summary

      by Margie Patlak, Sharyl J. Nass, and Erin Balogh, Rapporteurs; Institute of Medicine

      Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation. Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations. Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings.

      More
    • Monoclonal Antibodies in Oncology
      Oncology
      April 2013

      Monoclonal Antibodies in Oncology

      by Fatih M Uckun

      Monoclonal antibodies (mAbs) have been developed to improve the treatment outcome of cancer patients undergoing therapy according to multimodality regimens without a significant increase of treatment-associated toxicity. This five-chapter book provides examples where mAbs that have become part of the standard of care in cancer patients and cancer types that have responded to mAbs. Individual chapters devoted to each target cancer type illustrate the importance of recognizing and leveraging the unique features of the respective mAb in order to fully realize their therapeutic potential.

      More

    Subscribe to our

    newsletter

    Powered by:

    (c) Copyright 2025 - Frankfurt Rights. All Right Reserved